<DOC>
	<DOC>NCT01202253</DOC>
	<brief_summary>The purpose of this study is to describe the real world effectiveness of anidulafungin in clinical practice in a large Liver Unit in the United Kingdom.</brief_summary>
	<brief_title>Early Clinical Experience With Anidulafungin In Patients With Liver Disease In The United Kingdom</brief_title>
	<detailed_description>All subjects that have been treated with Anidulafungin according to its licence during the period of July 2009 and September 2010 will be included.</detailed_description>
	<mesh_term>Liver Diseases</mesh_term>
	<mesh_term>Candidiasis</mesh_term>
	<mesh_term>Anidulafungin</mesh_term>
	<mesh_term>Echinocandins</mesh_term>
	<criteria>Subjects who have been prescribed anidulafungin between 1st July 2009 and 30th September 2010. Patients admitted to specialist liver unit wards and the Liver Intensive Therapy Unit during this period Patients who participated in any interventional clinical trial during this episode of sepsis. Patients who received anidulafungin for infection prophylaxis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>March 2014</verification_date>
	<keyword>Ecalta</keyword>
	<keyword>Eraxis</keyword>
	<keyword>Candida</keyword>
	<keyword>Candidemia</keyword>
	<keyword>Systemic Candidiasis</keyword>
	<keyword>ICU</keyword>
	<keyword>Intensive Care Unit</keyword>
	<keyword>Critical Care Unit</keyword>
</DOC>